Type 2 diabetes is a disease in which your pancreas does not produce enough insulin, or your body does not properly use the insulin it makes, both of which can lead to uncontrolled blood sugar levels.

In a recent preclinical head-to-head study, DM-204 outperformed market approve therapies, by dramatically reducing blood sugar with the added benefit of reduced blood pressure and cholesterol levels. 

DM-204’s activity was measured in another study using the gold-standard hyperinsulinemic euglycemic clamp model. Animals treated with a single dose of DM-204 demonstrated a 291% increase in maximal glucose infusion rate (p<0.0035). This significant increase in glucose disposal was associated with a 160% overall average increase (p<0.0066) in the glucose infusion rate in order to maintain euglycemia.